SelectQuote, Inc. Form 8-K Summary
Business Context and Reporting Period
SelectQuote, Inc. filed a Form 8-K on December 2, 2022, reporting a corporate governance and capital-structure matter. The filing does not report quarterly or annual financial results and does not establish a new financial reporting period.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics. The filing text does not provide a clear value for these items.
Material Changes Versus the Prior Comparable Period
No period-over-period financial comparison or material operating change is disclosed. The company announced its intention to hold a special stockholder meeting on March 2, 2023, to seek approval for an amendment to its Sixth Amended and Restated Certificate of Incorporation that would authorize the Board of Directors, at its discretion, to effect a reverse stock split of the company’s common stock.
Guidance, Outlook, Risks, and Unusual Items
- The reverse stock split proposal requires stockholder approval and would remain subject to the Board’s discretion; the filing does not specify a split ratio.
- The company stated that it had notified the NYSE of its intent to cure a stock-price deficiency and referenced potential plans to do so. The filing does not provide a specific cure deadline or detailed remediation plan.
- The company expects to file a preliminary proxy statement on Schedule 14A and subsequently a definitive proxy statement. Stockholders are urged to review those materials when available.
- Forward-looking statements are subject to risks involving the company’s stock price, stockholder voting results, and other factors described in its Form 10-K for the year ended June 30, 2022, and subsequent SEC filings.
- The communication may constitute solicitation material relating to the reverse split proposal and is not presented as a complete basis for an investment decision.
Important Facts for Investors to Verify
- Whether the preliminary and definitive proxy statements are filed and the precise terms of the proposed reverse stock split.
- The record date, voting requirements, and outcome of the March 2, 2023 special meeting.
- The company’s NYSE listing status, stock-price deficiency details, cure deadline, and any subsequent compliance update.
- Any financial, capitalization, or trading effects resulting from a reverse stock split, if approved and implemented.
- Risk factors and financial condition disclosed in the company’s Form 10-K for the year ended June 30, 2022, and later filings.